Stanley Crooke on ASO Technology for Rare and Nanorare Diseases with n-Lorem

The Challenge of Rare Diseases

• 🎯 Rare diseases, by definition, affect small populations (fewer than a few hundred thousand), but collectively impact over 25 million people in the US.
• ⚠️ Patients often face long delays in diagnosis, care, and access to effective treatments, with many markets being too small for traditional drug companies.

The Genesis of n-Lorem

• 💡 Stanley Crooke, founder of Ionis Pharmaceuticals, was inspired to create n-Lorem after being unable to help families whose children had a rare genetic mutation (SCN2A) affecting ion channels.
• 🚀 Realizing his invented technology was efficient enough to create drugs for free for these ultra-rare conditions, he founded n-Lorem as a charitable foundation upon retiring from Ionis.
• 🔬 The foundation focuses on 'nanorare' diseases, defined by mutations expressed in fewer than 30 people worldwide, addressing the desperation and hopelessness faced by these patients.

Understanding ASO Technology

• 🧬 ASOs (Antisense Oligonucleotides) are chemically modified bits of genetic information used to target specific sites within cells.
• 🧩 This technology is ideal for genetic diseases because it uses genetic information to identify patients and create drugs, addressing the root cause rather than just symptoms.
• ⚡ ASO technology is significantly more efficient and precise than traditional drug discovery platforms.

Impact and Patient Success Stories

• ✅ Both boys with the SCN2A mutation initially brought to Crooke are now being treated by n-Lorem, with seizures controlled and significant regained skills, including independent walking for one.
• 🧠 These patients serve as unique scientific experiments, revealing that developmental delays may not be permanent and lost functions can be recovered.
• ✨ Crooke expresses increased optimism, noting that lost functions can be recovered and new functions can develop, challenging previous scientific assumptions.

ASOs vs. Gene Therapy

• ⚠️ The recent deaths of three patients in a gene therapy trial highlight the risks associated with large molecules like DNA and the need for immunosuppression.
• 🔬 ASOs are fundamentally different and have proven to be safe and effective, with established methods for development and delivery.
• ⏱️ n-Lorem aims to develop and treat a patient within 18-24 months, a stark contrast to the 18-24 years often seen in traditional drug development.

Cost and Accessibility

• 💰 The total cost to treat a patient for life with ASO technology is approximately $1 million, with a goal to reduce this to $800,000.
• 💔 This contrasts sharply with the immense financial and emotional burden placed on families of rare disease patients, who are often impoverished by the costs and lost hopes.
• 📈 Despite patients being diagnosed at advanced stages (average of 4.5 years from symptom onset), profound benefits are being observed.